Results 41 to 50 of about 825 (170)

Efficacy of blonanserin in the treatment of cognitive impairment in patients with schizophrenia

open access: yes, 2021
As a novel antipsychotic drug, the mechanism of action of blonanserin receptor makes it play an important role in improving cognitive dysfunction in patients with schizophrenia.
SunWeiming
core   +2 more sources

Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial

open access: yesBMJ Open, 2022
Introduction Both the pharmacological characteristics of blonanserin and its related small sample size studies suggest that blonanserin could alleviate social and cognitive dysfunctions in patients with schizophrenia.
Bin Wu   +11 more
doaj   +1 more source

A case of delusional parasitosis responded to blonanserin

open access: yesIndian Journal of Psychiatry, 2018
Anubhav Rathi, M. S. Bhatia
doaj   +3 more sources

A case of schizophrenia with relapsed catatonia successfully treated with blonanserin transdermal patch

open access: yesNeuropsychopharmacology Reports, 2023
Background Catatonia is a syndrome that may present with stupor, immobility, and postural retention, and appears in various primary disorders including schizophrenia, depressive disorders, and neurodevelopmental disorders.
Minako Hagikura, Toshiya Inada
doaj   +1 more source

Blonanserin overdose: A case report

open access: yesCHRISMED Journal of Health and Research, 2019
Sandeep Kumar Goyal, Parambir Singh
doaj   +2 more sources

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance

open access: yesFrontiers in Psychiatry, 2022
Schizophrenia is an unexplained, complex and serious mental illness. Blonanserin (BNS) is a new antipsychotic drug widely used in the treatment of schizophrenia. However, large-scale clinical studies have not been conducted in China.
Haishan Wu   +16 more
doaj   +1 more source

Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study [PDF]

open access: yes, 2019
© 2019 The Authors Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia. This study determined the efficacy, safety and pharmacokinetics of a blonanserin transdermal patch in patients with acutely ...
Sulaiman, A. H.   +10 more
core   +1 more source

Refractory dry eye disease associated with Meige’s syndrome induced by long-term use of an atypical antipsychotic

open access: yesBMC Ophthalmology, 2020
Background We report a case of Meige’s syndrome induced by an atypical antipsychotic (blonanserin) that presented with refractory dry eye disease. Case presentation A 37-year-old woman with a 6-month history of foreign body sensation in the eyes and ...
Ji Eun Kim, Ji Won Jung
doaj   +1 more source

Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity

open access: yes, 2020
Rationale Patients diagnosed with schizophrenia typically receive life-long treatments with antipsychotic drugs (APDs). However, the impact of chronic APDs treatment on neuroplastic mechanisms in the brain remains largely elusive.
Calabrese, Francesca   +8 more
core   +1 more source

Formulation and Evaluation of Transdermal Patch of Blonanserin

open access: yesInternational Journal of Pharmaceutical Sciences Review and Research, 2021
The objective of the present study was to formulate and evaluate transdermal patch of Blonanserin. Blonanserin transdermal patches were prepared by solvent casting method using natural and synthetic polymer. Various plastisizer were screened along with polymers.
Dhaval J. Patel   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy